Chemotherapy Regimens for Undifferentiated Spindle Cell Sarcomas

Standard Chemotherapy Regimens

The European Society for Medical Oncology recommends a combination of anthracyclines (doxorubicin) and alkylating agents (ifosfamid) as the standard chemotherapy regimen for undifferentiated spindle cell sarcomas 1
The combination of doxorubicin and cisplatin has been shown to be effective, according to the British Journal of Cancer guidelines 3, 4
The American College of Surgeons recommends that the treatment should be performed in specialized sarcoma centers with experience in treating these rare tumors 1

The National Comprehensive Cancer Network recommends preoperative (neoadjuvant) chemotherapy for 3 cycles, followed by surgery and 2 additional postoperative cycles, to reduce tumor size and increase the likelihood of complete resection with microscopically negative margins (R0) 5
Postoperative chemotherapy should be continued with the same regimen as preoperative chemotherapy, according to the British Journal of Cancer guidelines 3, 4

The use of G-CSF (granulocyte-colony stimulating factor) is recommended to manage neutropenia, according to the Journal of Clinical Oncology guidelines 6
In older patients (>65 years) or those with comorbidities, prophylactic use of G-CSF should be considered, according to the Journal of Clinical Oncology guidelines 6
Alternative regimens with gemcitabine/docetaxel or high-dose ifosfamid may be considered in patients with poor response to first-line therapy, according to the Annals of Oncology guidelines 1, 7

The cumulative dose of doxorubicin should be monitored to minimize cardiotoxic effects, according to the Annals of Oncology guidelines 7

Close follow-up with clinical examinations and imaging every 2-3 months for the first 2 years is recommended, according to the Praxis Medical Insights guidelines 2
CT thorax should be used to monitor for lung metastases, as this is the most common site of metastasis, according to the Annals of Oncology guidelines 8, 2